Dr. Joseph D’Orazio Provides Perspective to the New York Times on the Challenges That Will Still Exist Following the Designation of Xylazine as an ‘Emerging Drug Threat’

Joseph D’Orazio, MD, Associate Professor of Clinical Emergency Medicine at the Lewis Katz School of Medicine at Temple University, provided perspective to the New York Times for an article describing the challenges that will still exist following the designation of xylazine as an “emerging drug threat” by the White House’s Office of National Drug Control Policy. Xylazine, also known as tranq or tranq dope, is an animal sedative that has been increasingly found in fentanyl and heroin and causes fast-moving necrotic wounds and heavy sedation.